A Phase 3 interventional study of Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin) and Colchicine 0.5 mg in Atherothrombotic Diseases and Atherosclerotic Cardiovascular Disease (ASCVD), sponsored by Hospital do Coracao. Recruiting at 13 sites in Brazil. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by Hospital do Coracao · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing colchicine in Atherosclerosis — 7 open to participants now, 9 under way, 3 of them phase 3. Colchicine · Atherosclerosis.
Among the 17 studies testing colchicine in Atherosclerosis, this one has the largest planned enrollment, is one of 2 that started in 2025, is one of 5 in phase 3, and was the 13th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →7 of the 17 studies testing colchicine in Atherosclerosis are open now, in 7 countries. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 30–60
Instituto de Investigación Hospital Universitario La Paz · Sites in Spain
Ages 50+
Tan Tock Seng Hospital · Sites in Singapore
Ages 21–80
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Sir Run Run Shaw Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Colchicine: first FDA approval 1961 (COLBENEMID), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 45 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 7,713 is above the median of 100 across 881 interventional studies indexed under Atherosclerosis.
Median enrollment 115 across the 17 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 17 has an industry lead sponsor. The 10 most frequent:
Hospital do Coracao is the lead sponsor of 67 studies on the registry; 14 are open to participants now.
Hospital do Coracao has 1 study filed under Atherosclerosis — fewer than ten, so there is no comparison to draw.
3 of the studies testing colchicine in Atherosclerosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05476991Phase 3Assistance Publique - Hôpitaux de ParisEvaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis | 2027-09-01 |
| NCT05850091Massachusetts General HospitalPolygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine | 2027-06-01 |
| NCT07837934Tan Tock Seng HospitalColchicine for Primary Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies testing colchicine in Atherosclerosis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The EPOCA study (Evaluation of a POlypill and Colchicine for risk reduction in patients with established Atherosclerotic cardiovascular disease) will be a randomized, superiority, parallel, 2x2 factorial, multicenter clinical trial which will include at least 7713 and up to a maximum of 10797 participants with established atherosclerotic cardiovascular disease.
Cardiovascular disease is the leading cause of morbidity and mortality worldwide and in Brazil. Additionally, cardiovascular risk factors are highly prevalent conditions which are, frequently, present in association. Despite the last therapeutic advances, rates of adequate control of these conditions are still low. One proposed strategy to increase such control and decrease cardiovascular risk is the use of fixed-dose combinations of different pharmacological classes, to be taken on single daily dose - a polypill. This strategy has already been studied in other parts of the world, especially in patients with established or at risk for coronary heart disease (CHD).
Furthermore, there has been a need to explore other therapeutic targets beyond traditional risk factors that could impact the process of atherosclerosis. Among the various options evaluated, colchicine has emerged as a viable alternative, given its clinical use experience, mechanism of action, and the results showing a reduction in inflammatory biomarkers as well as clinical outcomes in individuals with different manifestations of coronary artery disease. However, it is important to highlight some key points regarding the available studies evaluating both the treatment strategy based on a polypill and the use of colchicine in the context of atherosclerotic cardiovascular disease (ASCVD).
The studies supporting both approaches were primarily conducted with participants with coronary artery disease from centers in Europe, the U.S., Iran, Oceania, and India, and there is a lack of robust evidence regarding these therapeutic strategies in other countries with a diverse population like Brazil, as well as in individuals with other manifestations of ASCVD (including peripheral arterial disease and cerebrovascular disease).
Given high prevalence of atherosclerotic cardiovascular disease and its traditional risk factors, low control rates, high levels of poor adherence and therapeutic inertia, and the specific realities of the population and healthcare system, evaluating the efficacy of a polypill strategy (fixed-dose an antihypertensive, aspirin, and high-potency statin) with a single daily dose, along with colchicine, in preventing cardiovascular events could contribute to improving cardiovascular care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cardiovascular Polypill + Colchicine 0.5 mg once daily
Drug: Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin) · Drug: Colchicine 0.5 mg
Cardiovascular Polypill + Colchicine placebo 0.5 mg once daily
Drug: Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin) · Drug: Colchicine-placebo 0.5 mg
Usual care + Colchicine 0.5 mg once daily
Drug: Colchicine 0.5 mg · Drug: Usual Care Group
Usual care + Colchicine placebo 0.5 mg once daily
Drug: Usual Care Group · Drug: Colchicine-placebo 0.5 mg
Cardiovascular Polypill contains Valsartan, Atorvastatin, Aspirin 1. Valsartan 160 mg + Atorvastatin 40 mg + Aspirin 100 mg or 2. Valsartan 160 mg + Atorvastatin 80 mg + Aspirin 100 mg or 3. Valsartan 320 mg + Atorvastatin 40 mg + Aspirin 100 mg or 4. Valsartan 320 mg + Atorvastatin 80 mg + Aspirin100 mg or 5. Valsartan 80 mg + Atorvastatin 40 mg + Aspirin 100 mg or 6. Valsartan 80 mg + Atorvastatin 80 mg + Aspirin 100 mg or 7. Valsartan 80 mg + Atorvastatin 20 mg + Aspirin 100 mg\* or 8. Valsartan 160 mg + Atorvastatin 20 mg + Aspirin 100 mg\* or 9. Valsartan 320 mg + Atorvastatin 20 mg + Aspirin 100 mg\* * The use of these formulations of the cardiovascular polypill will be restricted to cases of Statin-Related Muscle Symptoms (SRMS)
Colchicine 0.5 mg once daily
Patients allocated to the usual care arm will receive standard of care therapies for secondary prevention according to the guidelines. Drugs and doses will be left at the discretion of the treating physicians.
Matching Colchicine-placebo 0.5 mg once daily
Primary efficacy endpoint: Major adverse cardiovascular and limb events (MACLE)
Time to cardiovascular death, non-fatal type 1 myocardial infarction, non-fatal ischemic stroke, urgent arterial revascularization, and non-traumatic major lower limb amputation
Time frame: Through study completion, an estimated average of 3 years
Key secondary endpoint: Major adverse cardiovascular events (MACE)
Time to cardiovascular mortality, non-fatal type 1 myocardial infarction, and non-fatal ischemic stroke.
Time frame: Through study completion, an estimated average of 3 years
Cardiovascular death
Time to cardiovascular death
Time frame: Through study completion, an estimated average of 3 years
Non-fatal type 1 myocardial infarction
Time to non-fatal type 1 myocardial infarction
Time frame: Through study completion, an estimated average of 3 years
Non-fatal ischemic stroke
Time to non-fatal ischemic stroke
Time frame: Through study completion, an estimated average of 3 years
Change in Treatment Adherence
It will be assessed through the 9-item adapted Hill-Bone Medication Adherence Scale. The adapted 9-item Hill-Bone Medication Adherence Scale consists of 9 questions, each rated on a 4-point Likert scale ('all of the time', 'most of the time', 'some of the time', 'none of the time'). Item scores range from 1 to 4, yielding a total score between 9 and 36. Higher scores reflect poorer adherence, whereas lower scores reflect better adherence.
Time frame: Through study completion, an estimated average of 3 years
Change in Systolic and Diastolic Blood Pressure (SBP and DBP)
Systolic and diastolic blood pressure will be assessed and summarized at each timepoint.
Time frame: Through study completion, an estimated average of 3 years
Change in serum LDL-c concentrations
Non-fasting blood analysis will be collected and LDL cholesterol level evaluated at each timepoint.
Time frame: Through study completion, an estimated average of 3 years
Change in serum concentrations of high-sensitivity C-reactive protein (hs-CRP)
High-sensitivity C-reactive protein (hs-CRP) will be colllected and evaluated at each timepoint
Time frame: Through study completion, an estimated average of 3 years
Proportion of individuals with controlled blood pressure
Systolic and diastolic blood pressure will be collected and the proportions of patients with controled blood pressure will be summarized at each timepoint
Time frame: Through study completion, an estimated average of 3 years
Proportion of individuals with LDL-c levels at target
Non-fasting blood analysis will be collected and the proportion of individuals with LDL-c levels at target will be evaluated at each timepoint
Time frame: Through study completion, an estimated average of 3 years
Change in Quality of Life
The European Quality of Life - 5 Dimensions 5 Levels (EQ-5D-5L) Questionnaire will be administered at each timepoint to evaluate changes in quality of life. The EQ-5D-5L includes a descriptive system and a visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression-each with five levels of severity. Responses generate a five-digit health profile. The EQ VAS captures the participant's self-rated health on a visual scale from 0 ("the worst health you can imagine") to 100 ("the best health you can imagine").
Time frame: Through study completion, an estimated average of 3 years
Safety endpoint: All-cause death
Time to all-cause death
Time frame: Through study completion, an estimated average of 3 years
Safety endpoint: Bleeding
It will be assessed according to the definitions of the Bleeding Academic Research Consortium.
Time frame: Through study completion, an estimated average of 3 years
Safety endpoint: Hospitalization for sepsis
Time to hospitalization for sepsis
Time frame: Through study completion, an estimated average of 3 years
Safety endpoint: new diagnonis of cancer
Time of ocurrence of new diagnosis of cancer
Time frame: Through study completion, an estimated average of 3 years
Plan to share: Yes — Our data dissemination plan will follow the rules of the Hcor research institute
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: 1 year after the publication
Access criteria: Submission of a statistical analysis plan for the purposed analyses. Compliance with Brazilian. data privacy law.
Started Jun 2025 (actual). Primary completion is estimated for May 2031, 71 months after the start.
Of 54 phase 3 interventional studies under Atherosclerosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's planned 71 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Colchicine
Hospital do Coracao